cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Xencor Inc
1 own
4 watching
Current Price
$35.72
$-0.9
(-2.46%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,135.1M
52-Week High
52-Week High
38.2
52-Week Low
52-Week Low
19.355
Average Volume
Average Volume
0.41M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
107.3906
iconMarket Capitalization2,135.1M
icon52-Week High38.2
icon52-Week Low19.355
iconAverage Volume0.41M
iconDividend Yield--
iconP/E Ratio107.3906
What does the Xencor Inc do?
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies. Its product candidates also comprise XmAb5574/MOR208, which is in Phase II clinical trials for the treatment of non-Hodgkin lymphomas and chronic lymphocytic leukemia; and XmAb13551 that is in preclinical trials used for the treatment of multiple myeloma. The company has license agreement with Amgen Inc. and MorphoSys Ag to develop and commercialize bispecific antibody product candidates; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.
Read More
How much money does Xencor Inc make?
News & Events about Xencor Inc.
Globe Newswire
2days ago
SAN CARLOS, Calif., and MONROVIA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, ...
Business Wire
1month ago
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced additional clinical data from expansion cohorts in its Phase 1 study of plamotamab, a CD20 x CD3 bispecific...
Ticker Report
2 months ago
StockNews.com upgraded shares of Xencor (NASDAQ:XNCR Get Rating) from a sell rating to a hold rating in a research report released on Monday morning. XNCR has been the subject of several other research reports. Raymond James upgraded Xencor from an outperform rating to a strong-buy rating ...
Business Wire
3 months ago
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of data from the first patients in the Phase 2 combination study of vudalimab, a selective PD-1...
Business Wire
4 months ago
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced seven poster presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, being held in...
Frequently Asked Questions
Frequently Asked Questions
What is Xencor Inc share price today?
plus_minus_icon
Can Indians buy Xencor Inc shares?
plus_minus_icon
How can I buy Xencor Inc shares from India?
plus_minus_icon
Can Fractional shares of Xencor Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Xencor Inc stocks?
plus_minus_icon
What is today’s traded volume of Xencor Inc?
plus_minus_icon
What is today’s market capitalisation of Xencor Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Xencor Inc?
plus_minus_icon
What percentage is Xencor Inc down from its 52-Week High?
plus_minus_icon
What percentage is Xencor Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$35.72
$-0.9
(-2.46%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
$30.93
$0.61 (2.01 %)
MacroGenics, Inc.
MacroGenics, Inc.
$5.71
$-0.08 (-1.38 %)
CytomX Therapeutics Inc
CytomX Therapeutics Inc
$2.75
$-0.09 (-3.17 %)
Blueprint Medicines Corp
Blueprint Medicines Corp
$45.85
$0.18 (0.39 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
$30.93
$0.61 (2.01 %)
MacroGenics, Inc.
MacroGenics, Inc.
$5.71
$-0.08 (-1.38 %)
CytomX Therapeutics Inc
CytomX Therapeutics Inc
$2.75
$-0.09 (-3.17 %)
Blueprint Medicines Corp
Blueprint Medicines Corp
$45.85
$0.18 (0.39 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00